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Abstract
Host cell invasion by apicomplexan pathogens such as the malaria parasite Plasmodium spp. and Toxoplasma gondii involves
dischargeofproteinsfrom secretory organellescalledmicronemesandrhoptries.InToxoplasma aprotein complexcomprising
the microneme apical membrane antigen 1 (AMA1), two rhoptry neck proteins, and a protein called Ts4705, localises to the
moving junction, a region of close apposition between parasite and host cell during invasion. Antibodies against AMA1
prevent invasion and are protective in vivo, and so AMA1 is of widespread interest as a malaria vaccine candidate. Here we
report that the AMA1 complex identified in Toxoplasma is conserved in Plasmodium falciparum. We demonstrate that the
invasion-inhibitory monoclonal antibody (mAb) 4G2, which recognises P. falciparum AMA1 (PfAMA1), cannot bind when
PfAMA1 is in a complex with its partner proteins. We further show that a single completely conserved PfAMA1 residue, Tyr251,
lying within a conserved hydrophobic groove adjacent to the mAb 4G2 epitope, is required for complex formation. We
propose that mAb 4G2 inhibits invasion by preventing PfAMA1 from interacting with other components of the invasion
complex. Our findings should aid the rational design of subunit malaria vaccines based on PfAMA1.
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Introduction
Malaria is a global problem, affecting many of the world’s
poorest nations. Around 40% of the world’s population is at risk
from the disease with over 500 million clinical cases yearly, and
malaria is a major cause of mortality in children under five. Of
particular concern, the emergence of insecticide-resistant mosquito
vectors and multi-drug resistant parasites has contributed to
resurgences of the disease in areas where it was previously under
control. Malaria is caused by protozoan parasites of the genus
Plasmodium, with the most severe disease being the result of
infection with P. falciparum. The malaria merozoite invades
erythrocytes and undergoes rounds of asexual replication (schi-
zogony) to generate a schizont containing multiple daughter
merozoites. Upon schizont rupture, the merozoites are released to
invade new erythrocytes. Repetitive cycles of invasion, replication
and schizont rupture are responsible for the clinical symptoms of
the disease. The development of a malaria vaccine and the
identification of new parasite targets for chemotherapeutic
intervention are important ways forward in combating the disease.
Erythrocyte invasion by the merozoite proceeds in several
rapidly consecutive steps. Initial low affinity binding to the host cell
is followed by reorientation of the parasite so that its apical
prominence is in close apposition with the host cell surface,
formation of an intimate, electron-dense point of contact or
‘junction’ between parasite and host cell, then movement of the
parasite into the parasitophorous vacuole, concomitant with
translocation of this ‘moving junction’ across the parasite surface.
Invasion is orchestrated by proteins released from merozoite apical
secretory organelles called micronemes and rhoptries. Apical
membrane antigen 1 (AMA1) is a type I integral membrane
protein that plays an essential role in invasion. In P. falciparum it is
synthesised during schizogony as an 83 kDa precursor called
PfAMA183 [1] and targeted to micronemes [2,3]. Prior to invasion
it is proteolytically processed to a 66 kDa form (PfAMA166) that
translocates onto the merozoite surface [1,4] from where it is
eventually shed during invasion by a membrane-bound subtilisin-
like protease called PfSUB2 [5–7]. Homologues of AMA1 are
present in all species of Plasmodium and in all other apicomplexan
genera examined [8–11]. In P. falciparum [12], Toxoplasma gondii
[13], and recently in the rodent malaria P. yoelii [14], AMA1 has
been shown to interact with the essential rhoptry neck protein
RON4. In T. gondii the AMA1/RON4 complex associates with the
moving junction during invasion [12,15]. Two additional AMA1-
associated proteins (AAPs) have been identified in T. gondii; these
are the rhoptry neck protein RON2 and a previously unchar-
acterised protein called Ts4705. Although homologues of both
proteins exist in Plasmodium, evidence to suggest any association
between these molecules and the PfAMA1-PfRON4 complex in P.
falciparum is lacking.
The AMA1 ectodomain comprises three disulphide-constrained
domains [16–18]. Immunisation with AMA1 or recombinant
fragments of it can protect against blood-stage malarial infection,
and antibodies against AMA1 inhibit erythrocyte invasion. As a
result, AMA1 is of widespread interest as a malaria vaccine
candidate (recently reviewed by Remarque et al. [19]). As with
many malarial antigens, PfAMA1 exhibits significant polymor-
phism [20,21], believed to facilitate evasion of inhibitory
antibodies. The mechanism(s) of action of invasion-inhibitory
anti-AMA1 antibodies has been a subject of considerable interest,
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may act by inhibiting translocation of AMA1 across the merozoite
surface and its subsequent shedding by PfSUB2 [22], an
alternative possibility is that antibodies may bind regions of the
AMA1 ectodomain that are functionally important. Monoclonal
antibody (mAb) 4G2 is a potent inhibitor of erythrocyte invasion
by all strains of P. falciparum [23]. We previously demonstrated that
the residues recognised by mAb 4G2 lie exclusively within the base
of a loop in domain II of the PfAMA1 ectodomain [17,24]. While
the bulk of this loop extends across the non-polymorphic face of
domain I, two residues of the loop (Lys357 and Phe367) form part
of a conspicuous, surface-exposed, conserved hydrophobic trough
in domain I that is surrounded by polymorphic residues [18]. No
polymorphic residues have been identified within the domain II
loop itself, suggesting that variation within this region of the
molecule is functionally constrained [20]. If the domain II loop
and adjacent residues are of functional importance, mAb 4G2 may
act by blocking this function.
Here we provide evidence that this is indeed the case. We first
demonstrate that the homologues of all three Toxoplasma AAPs are
expressed in P. falciparum and interact specifically with PfAMA1.
We then show that, in contrast to polyclonal antibodies against the
PfAMA1 ectodomain, mAb 4G2 can bind PfAMA1 only when it is
not in a complex with AAPs. Using transgenic expression of
PfAMA1 mutants in the parasite we demonstrate that substitution
of selected residues close to the 4G2 epitope and within the
hydrophobic trough of PfAMA1, abolishes binding to RON4 and
the other AAPs. Our findings suggest that mAb 4G2 inhibits
invasion by blocking the formation of a functional complex
between PfAMA1 and other components of the moving junction.
Results
PfAMA1 forms a complex with three AAPs
In both Toxoplasma and Plasmodium, AMA1 interacts with the
rhoptry neck protein RON4 [12–14]. Two additional AAPs,
TgRON2 and Ts4705, were identified in Toxoplasma, both of
which have putative homologues in P. falciparum [12,13,15]. To
fully characterise the PfAMA1-PfRON4 complex, we used the
anti-PfAMA1 polyclonal serum N5 [24] and the anti-PfRON4
mAb 24C6 [25], both of which are highly specific for their cognate
antigens on Western blots (Figure 1A). When used to immuno-
precipitate (IP) from parasite extracts, both antibodies co-
precipitated the reciprocal protein(s) as expected, plus in both
cases two species at ,190 kDa and 110 kDa (Figure 1B). These
latter proteins were unequivocally identified by matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF) analysis
of tryptic peptide digests as products of P. falciparum genes
Pf14_0495 (the homologue of TgRON2, hereafter referred to as
PfRON2) and Mal8P1.73 (the P. falciparum homologue of Ts4705)
respectively (Tables S1, S2, S3). These findings confirm that the
invasion complex previously identified in Toxoplasma is conserved
in its entirety in P. falciparum.
The invasion-inhibitory mAb 4G2 cannot bind the intact
PfAMA1-AAP complex
We repeated the above IP experiments using mAb 4G2. As
shown in Figure 2A, whilst both PfAMA183 and PfAMA166 were
Author Summary
Malaria is caused by a singe-celled parasite that invades
and grows within red blood cells. Many available
antimalarial drugs are increasingly ineffective, and there
is no vaccine. Certain malarial proteins induce protective
antibody responses that prevent red cell invasion. This
study focuses on the mechanism by which an antibody
called 4G2, specific for a parasite protein called AMA1,
prevents invasion. Just before invasion, AMA1 is dis-
charged onto the parasite surface, where it interacts with
other parasite proteins at a transient structure called the
‘moving junction’, through which the parasite moves as it
enters the cell. We have identified all the components of
this protein complex in Plasmodium falciparum, the
causative agent of the most dangerous form of malaria.
We show that whereas 4G2 can bind to free AMA1, it
cannot bind when AMA1 is in a complex with its partner
proteins. This suggests that antibody binding just before
invasion prevents assembly of the complex. In support of
this, we show that amino acids within a surface-located
‘hydrophobic trough’ on AMA1, very close to the site
recognised by 4G2, are involved in formation of the AMA1
complex. These findings suggest ways in which to
optimally design antimalarial vaccines based on AMA1.
Figure 1. The PfAMA1 complex comprises PfAMA1 plus three
AAPs. (A). Western blot of schizont extracts, demonstrating the
specificity of binding of anti-PfAMA1 serum N5 and mAb 24C6 for
PfAMA1 and PfRON4 respectively. Signals of the expected sizes were
obtained, with no evidence for cross-reactivity. (B). Anti-PfAMA1 serum
N5 and mAb 24C6 both precipitate PfRON4 and PfAMA1, plus two
additional proteins of ,190 kDa and 110 kDa. These were identified by
mass spectrometric tryptic peptide mapping as PfRON2 and Mal8P1.73
respectively (Tables S1, S2, S3). IPs were from extracts of biosynthet-
ically radiolabelled schizonts. Note that both the mature and processed
forms of PfAMA1 were co-precipitated by mAb 24C6, suggesting that
PfRON4 is able to interact with both forms of PfAMA1. NMS, normal
mouse serum. Positions of molecular mass marker proteins are
indicated (kDa).
doi:10.1371/journal.ppat.1000273.g001
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in this case. This suggested that either mAb 4G2 is unable to
recognise the intact complex, binding only free PfAMA1 present in
the extracts, or that addition of mAb 4G2 to the schizont extracts
disrupts any existing PfAMA1-AAP complex. To distinguish
between these possibilities, parasite extracts were subjected to
immuno-depletion using either polyclonal serum N5 or mAb 4G2,
followed by IP with either the reciprocal antibody or the anti-
PfRON4 mAb 24C6. As shown in Figure 2B, N5 depleted
virtually all PfAMA1 in the samples, including most of the
PfAMA1-AAP complex. In contrast, two rounds of depletion with
mAb 4G2 precipitated free PfAMA1 but did not result in any AAP
co-precipitation, whereas subsequent IP with either N5 or mAb
24C6 precipitated the PfAMA1-AAP complex. These results
indicate that mAb 4G2 does not destabilise the PfAMA1-AAP
complex, but specifically cannot bind it. Comparison of the
relative amounts of PfAMA1 immunoprecipitated by mAb 4G2 in
two rounds of depletion and subsequently by N5, confirmed
previous findings in Toxoplasma [12,26] that in the parasite most
AMA1 is not associated with the AAPs. It was also interesting to
note that, following depletion of essentially all the PfAMA1 with
N5, IP with anti-PfRON4 mAb 24C6 resulted in efficient co-
precipitation of PfRON2 and Mal8P1.73, indicating that these
three AAPs are able to interact in the absence of PfAMA1.
Collectively, these results lead to two conclusions: first, they show
that the 4G2 epitope cannot be accessed by mAb 4G2 in the intact
PfAMA1-AAP complex; and second, they show that the three
AAPs can associate with each other independently of PfAMA1.
Figure 2. Invasion-inhibitory mAb 4G2 does not bind the PfAMA1-AAP complex. (A). Immunoprecipitation from extracts of
biosynthetically radiolabelled schizonts with control normal mouse serum (NMS), polyclonal anti-PfAMA1 serum N5, mAb 4G2 and anti-PfRON4
mAb 24C6. Although mAb 4G2 efficiently precipitated PfAMA1, it did not co-precipitate any of the three AAPs (indicated). These results were
completely reproducible in 10 independent immunoprecipitation experiments. (B). Immuno-depletion experiments. Schizont extracts were subjected
to two consecutive rounds of depletion (labelled 1 and 2) using either anti-PfAMA1 serum N5, or mAb 4G2, or control normal mouse serum (NMS),
followed in each case by IP from the depleted extracts with the reciprocal antibody or mAb 24C6. Each track contains proteins eluted with SDS from
the immunoprecipitation matrix. Depletion of the PfAMA1-AAP complex could not be achieved using mAb 4G2, even though it efficiently bound free
PfAMA1. In all cases, immunoprecipitated proteins were detected by fluorography. Note that the slight differences in profile at ,50 kDa in some of
the tracks is due to the presence of (unlabelled) immunoglobulin heavy chain on the gels, and the fact that the rat mAb 4G2-derived heavy chain
migrates slightly higher on SDS PAGE than that of the mouse antibodies.
doi:10.1371/journal.ppat.1000273.g002
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interacts with AAPs
The above results suggested that mAb 4G2 may interact with a
region of PfAMA1 involved in AAP complex formation. To
investigate this possibility, we adopted a strategy of expression of
pfama1 transgenes in the parasite. We have previously demonstrated,
using allelic replacement via homologous recombination, that a
synthetic re-codonised pfama1 gene (ama-1syn) can fully complement
the function of the endogenous pfama1 gene [24]. For the current
study, a construct was designed to obtain episomal expression of the
ama-1syn gene, modified by insertion of a haemagglutinin (HA)
epitope tag within a loop in domain III of the PfAMA1 ectodomain.
Parasites transfected with this plasmid were expected to express the
tagged transgene under control of the pfama1 promoter, on a
background of expression of the endogenous allele. To determine
whether the transgene product (called PfAMA1/DIII-HA) was
correctly trafficked in P. falciparum, a parasite line harbouring the
construct was analysed by Western blot using polyclonal anti-
PfAMA1 antibodies (which recognise both endogenous and episomal
gene products) and the anti-HA mAb 3F10. As shown in Figure 3,
PfAMA183 and the processed PfAMA166 form were detectable in
both transgenic and parental wild-type parasites with polyclonal anti-
PfAMA1 serum R5, but were detected only in transgenic parasites
with the HA-specific mAb 3F10 (Figure 3A). This indicated that the
epitope-tagged PfAMA1/DIII-HA was expressed and correctly
processed in the transgenic parasites, in turn suggesting its correct
trafficking tothemicronemes(where processing toPfAMA166 occurs;
[1,3]). The PfAMA1/DIII-HA product was also correctly shed into
culture supernatants following merozoite release (Figure 3A, CS
lanes). Interestingly, none of the transgenic protein was shed in the
minor PfAMA144 form, likely due to the fact that the HA epitope tag
within the domain III loop straddles the internal ‘‘nick’’ site at
Asn464, preventing the usual partial cleavage that occurs at this site
around the time of PfSUB2-mediated shedding [6]. Correct
trafficking of the transgene product was confirmed by IFA using
mAb 3F10 (Figure 3B–D); expression of PfAMA1/DIII-HA was
detected at the apical prominence of both intracellular and free
transgenic merozoites in a pattern identical to that observed with
antibodies to PfAMA1 and to another microneme protein, EBA-175,
but distinct from that seen with the rhoptry-specific mAb 24C6.
Peripheral membrane staining was also observed on free merozoites
with mAb 3F10 (Figure 3C, merozoites), confirming that PfAMA1/
DIII-HA was correctly translocated from micronemes onto the
merozoite surface following schizont rupture.
To determine whether the PfAMA1/DIII-HA gene product is
able to interact with endogenous AAPs, transgenic parasites were
analysed by IP using the anti-PfRON4 mAb 24C6. PfAMA1/
DIII-HA was efficiently co-precipitated (Figure 3E). The specificity
of this interaction was confirmed by immunoprecipitation with
mAb 24C6 from extracts of a different transgenic P. falciparum
clone in which the chromosomal PfSUB2 gene has been modified
by fusion to a C-terminal triple-HA tag [5]; like PfAMA1, PfSUB2
is trafficked to micronemes and eventually relocated onto the
merozoite surface. Immunoprecipitation with mAb 24C6 from this
clone did not result in co-precipitation of HA-tagged PfSUB2
(Figure 3E). Collectively, these results show that episomally-
expressed PfAMA1/DIII-HA is correctly expressed, trafficked and
processed in P. falciparum, and that it interacts with PfRON4 in a
manner similar to endogenous PfAMA1.
The base of the PfAMA1 domain II loop does not play a
role in interaction with AAPs
To examine the structural requirements for the interaction
between PfAMA1 and the AAPs, we next expressed a range of
Figure 3. Correct trafficking and post-translational processing
of episomally expressed PfAMA1. (A). Western blot of parental 3D7
and transgenic parasite lines harbouring a construct for expression of
PfAMA1/DIII-HA. Anti-PfAMA1 serum R5 detected mature and pro-
cessed forms of PfAMA1 in both parental and transgenic lines, whilst
the epitope-tagged protein detected with the anti-HA mAb 3F10 (aHA)
was present only in transgenic parasites. S, schizont extracts; CS, culture
supernatants. (B)–(D). IFA of the PfAMA1/DIII-HA line probed with the
anti-PfRON4 mAb 24C6, a rabbit anti-PfAMA1 polyclonal serum
(RbaAMA1), mAb 3F10 (aHA), or a rabbit polyclonal anti-EBA-175
serum (RbaEBA). (E). Proteins immunoprecipitated with anti-PfRON4
mAb 24C6 from extracts of the PfAMA1/DIII-HA and PfSUB2-HA lines,
analysed by Western blot with mAb 3F10 (aHA) or anti-PfAMA1 serum
R5. Whilst PfAMA1 was efficiently co-precipitated from both extracts, no
mAb 3F10-reactive species were co-precipitated from extracts of the
PfSUB2-HA clone (note that mature PfSUB2-HA migrates on SDS-PAGE
at ,75 kDa; [5]).
doi:10.1371/journal.ppat.1000273.g003
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their capacity to interact with PfRON4. In view of the above
evidence suggesting possible overlap between the mAb 4G2
epitope and the AAP binding site(s) on PfAMA1, we first explored
residues directly involved in recognition of PfAMA1 by mAb 4G2.
Six mutant constructs were produced, designed to express the
single residue alanine substitution mutants PfAMA1/DIII-HA-
D348/A, PfAMA1/DIII-HA-K351/A, PfAMA1/DIII-HA-
Q352/A, PfAMA1/DIII-HA-D388/A, PfAMA1/DIII-HA-
R389/A, and PfAMA1/DIII-HA-F385/A. All these residues have
previously been shown to be required for mAb 4G2 binding
[17,24]. An additional construct was also produced for expression
of PfAMA1/DIII-HA-K351/T+R389/N, in which two residues
were substituted with the corresponding residues from AMA1 of
the human malaria parasite P. vivax. Mutant constructs were
transfected into P. falciparum and the resulting transgenic lines
examined as above. As shown in Figure 4, all the mutant proteins
were expressed and correctly processed (although mutant
PfAMA1/DIII-HA-D348/A appeared to be processed to the
PfAMA166 form rather inefficiently, perhaps due to the previously
noted structurally destabilising effect of this particular mutation
[24]). Furthermore all interacted efficiently with PfRON4 as
shown by co-precipitation with the anti-PfRON4 mAb 24C6. It
was concluded that the individual residues known to be required
for binding of mAb 4G2 to PfAMA1 are not essential for
formation of the PfAMA1-AAP complex.
Hydrophobic trough residues are involved in the
interaction between PfAMA1 and AAPs
Our previous analysis of the mAb 4G2 epitope has shown that it
lies adjacent to a conspicuous groove on the surface of domain I of
the PfAMA1 ectodomain (Figure 5A). Referred to as the
hydrophobic trough, it is made up of residues that are mostly
conserved across all Plasmodium species examined to date, and are
conserved with respect to their hydrophobicity in all apicomplexan
AMA1 sequences so far identified [18]. Of particular note, the
trough lies adjacent to the mAb 4G2 epitope, raising the possibility
that, if it plays a role in AAP binding, binding of AAPs to the
trough might interfere with mAb 4G2 binding. Also, on the other
side of the trough lies a highly polymorphic residue, Glu197,
essential for binding of another, strain-specific invasion-inhibitory
mAb called 1F9 [21,27]. To explore whether the hydrophobic
trough plays a role in PfAMA1-AAP complex formation, a further
set of constructs were produced to express PfAMA1/DIII-HA
mutants possessing substitutions or deletions within or adjacent to
the trough. Mutants PfAMA1/DIII-HA-HT1 and PfAMA1/DIII-
HA-HT2 possess alanine substitutions of aromatic residues
Phe183 and Tyr251 - which lie at the centre of the trough within
6.7 A ˚ of each other – plus substitutions of either residues Ile190,
Tyr202 and Met224 (PfAMA1/DIII-HA-HT1; Figure 5B left-
hand side) or Val169, Ile252, Leu357 and Phe367 (PfAMA1/DIII-
HA-HT2; Figure 5B centre). Mutant PfAMA1/DIII-HA-HT3, in
contrast, possessed alanine substitutions of just two conserved
residues, Leu357 and Phe367, which lie in the domain II loop and
form part of one end of the hydrophobic trough (Figure 5B right-
hand side). Three further deletion mutants were produced called
PfAMA1/DIII-HA-DH1, PfAMA1/DIII-HA-DH2, and
PfAMA1/DIII-HA-DH1+2 (Figure 5C). These lack respectively
the first, the second, or both of two stretches, Tyr353-Lys368 and
Asp373-Ser377, within the upper part of the domain II loop
adjacent to the trough. Constructs for episomal expression of all
six mutants were transfected into P. falciparum and the resulting
transgenic lines examined as previously. Analysis of mutant
PfAMA1/DIII-HA-HT2 by IFA showed that it was correctly
trafficked, but further examination by immunoprecipitation and
Western blot indicated it degraded rapidly following detergent
extraction of schizonts, possibly due to destabilisation of the global
fold of the molecule (data not shown). As shown in Figure 6, all the
other mutant transgene products were correctly expressed and
processed, and could be detected by Western blot in extracts or
culture supernatants of the lines (Figure 6A). Immunoprecipitation
with mAb 24C6 (Figure 6B) showed that all three deletion mutants
and PfAMA1/DIII-HA-HT3 were co-precipitated with PfRON4,
indicating that they efficiently formed a complex with this AAP. In
contrast, mutant PfAMA1/DIII-HA-HT1 did not co-precipitate
with PfRON4, even though it was properly trafficked (Figure 6C)
and even though endogenous PfAMA1 was efficiently co-
precipitated from extracts of this same line. This strongly suggests
that one or more of the hydrophobic trough residues Ile190,
Tyr202, Met224, Phe183 and Tyr251 are critical for formation of
the PfAMA1-AAP complex.
Figure 4. Mutations within the 4G2 epitope do not prevent PfAMA1-PfRON4 interaction. (A). Western blot of immunoprecipitates from
parasite lines expressing various mutants of PfAMA1/DIII-HA. IP was performed with the anti-PfRON4 mAb 24C6. (B). Western blot of culture
supernatants (CS) collected from the same lines. Blots were probed with either anti-PfAMA1 serum R5 or anti-HA mAb 3F10 (aHA). Parasite lines
expressing PfAMA1/DIII-HA and mutants thereof exhibited no discernible growth phenotype (data not shown).
doi:10.1371/journal.ppat.1000273.g004
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possessing alanine substitutions of the two central trough residues
Phe183 and Tyr251, either separately (PfAMA1/DIII-HA-HTF
and PfAMA1/DIII-HA-HTY), or together (mutant PfAMA1/
DIII-HA-HTFY; see Figure 5D), were produced and evaluated in
the same way. As with the other mutants shown in Figure 5, these
were correctly trafficked and processed (not shown). As shown in
Figure 6D, whereas mutation of just Phe183 alone resulted in a
Figure 5. PfAMA1 mutations explored within and flanking the hydrophobic trough. (A). Two views of the molecular surface
representation of the PfAMA1 model based on the x-ray crystal structures of PfAMA1 and PvAMA1. Domain I is shown in red, domain II in blue,
domain III in mustard, the hydrophobic trough in grey, the 4G2 epitope in black and the mAb 1F9 epitope residue Glu197 in green, visible on the left
in the 90u rotated view. (B). Hydrophobic trough substitution mutants. PfAMA1 view as shown in (A) right-hand side, with from left to right mutants
PfAMA1/DIII-HA-HT1 (Phe183, Ile190, Tyr251, Tyr202, Met224 in white), PfAMA1/DIII-HA-HT2 (Val169, Phe183, Tyr251, Ile252, Leu357, Phe367 in white)
and PfAMA1/DIII-HA-HT3 (Leu357, Phe367 in white). (C). Deletion mutants. PfAMA1 view as shown in (B) showing in white the domain II loop residues
removed in mutants PfAMA1/DIII-HA-DH1, PfAMA1/DIII-HA-DH2 and PfAMA1/III-HA-DH1+2. (D). Phe183/Tyr251 substitution mutants. PfAMA1 view
as shown in (B) with, from left to right, mutants PfAMA1/DIII-HA-HTF, -HTY and –HTFY. Residues substituted with alanine are in each case shown in
white. Figures were created using PyMOL (DeLano Scientific).
doi:10.1371/journal.ppat.1000273.g005
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containing the Tyr251Ala substitution were severely impaired in
their ability to interact with RON4. Taken together with the
absence of binding displayed by mutant PfAMA1/DIII-HA-HT1,
these results strongly suggest that the central trough residue
Tyr251 (which is completely conserved across all apicomplexan
AMA1 sequences) plays a critical role in AAP complex binding. In
view of the proximity of this residue to those comprising the 4G2
epitope (less than 30 A ˚; Figure 5), our results strongly suggest that
the inability of mAb 4G2 to recognise the PfAMA1-AAP complex
is a result of steric hindrance or local conformational changes
introduced into PfAMA1 by the bound AAP complex. Given the
Figure 6. PfAMA1 hydrophobic trough residues are critical for interaction with PfRON4. (A). Western blot of total schizont extracts (S) and
culture supernatants (CS) from parasite lines expressing deletion mutants (PfAMA1/DIII-HA-DH1, -DH2, and DH1+2) and hydrophobic trough mutants
(PfAMA1/DIII-HA-HT1 and -HT3). Blots were probed with the anti-HA mAb 3F10 (aHA). (B). Western blot of IPs from extracts of the same lines, probed
with anti-HA mAb 3F10 (aHA) or anti-PfAMA1 serum R5. IP was performed using anti-PfRON4 mAb 24C6. (C). IFA of schizonts from lines expressing
mutants PfAMA1/DIII-HA-HT1 and -HT3, showing identical sub-cellular localisation of the mutant transgene product, detected by mAb 3F10 (aHA),
with the microneme marker EBA-175 (RbaEBA). (D). Western blot of IPs from extracts of the Phe183 and Tyr251 mutants (PfAMA1/DIII-HA-HTFY, -HTF
and –HTY), probed with anti-HA mAb 3F10 (aHA) or anti-PfAMA1 serum R5. IP was performed using anti-PfRON4 mAb 24C6. Note that all these
mutants except PfAMA1/DIII-HA-DH1 and -DH1+2 (consistent with our previous findings, [24]) were reactive with the anti-PfAMA1 mAb 4G2 (Figure
S1) confirming that they were conformationally correct.
doi:10.1371/journal.ppat.1000273.g006
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likely to be true: binding of mAb 4G2 to free PfAMA1 is likely to
prevent formation of the PfAMA1-AAP complex.
Discussion
The molecular role of AMA1 has been a subject of considerable
investigation, but remains poorly understood. Gene disruption
attempts in haploid stages of Plasmodium and Toxoplasma [8,28]
were important in indicating that AMA1 is essential for parasite
viability. More insight into its role has been derived from
approaches that more subtly interfere with its function. Using an
elegant gene knockdown system in Toxoplasma, Mital et al. [26]
showed that parasites expressing AMA1 at ,0.5% of wild-type
levels exhibit a block in the second, intimate attachment step of
host cell invasion, as well as a defect in rhoptry secretion. An
electron microscopic study on the effects of an invasion-inhibitory
mAb specific for AMA1 of the simian malaria species P. knowlesi
observed that arrested extracellular merozoites had formed initial
attachments with the host erythrocyte but not the close range
interactions required for junction formation [29]. Together with
the revelations of Alexander et al. [12,13] showing an association
with AMA1 with AAPs in the moving junction, these data are all
consistent with a role for AMA1 in assembly of this remarkable
structure, certainly as a structural component of the junction and
possibly also as a mediator of the signal(s) that triggers discharge of
RON4 and the other AAPs to form the AMA1-AAP complex.
How do the results of the present study contribute to this picture?
Three major conclusions can be drawn from our findings, as
follows. First, that the AMA1-AAP complex first identified in
Toxoplasma is entirely conserved in the human malaria parasite P.
falciparum. Second, that the intact complex, although present in
detergent extracts of mature P. falciparum schizonts, is selectively not
recognised by the invasion-inhibitory mAb 4G2. Third, that certain
residues within the hydrophobic trough, a prominent and conserved
featureofthemembrane-distaldomainIofthemolecule,areessential
for PfAMA1-AAP complex formation. Some of the mutations we
introduced into our episomally-expressed PfAMA1 constructs to
investigate the requirements for AAP binding could have introduced
far-reaching structural changes into the molecule, necessitating
c a u t i o ni nt h ei n t e r p r e t a t i o no fs o m eo fo u rr e s u l t s .A sa ne x a m p l e
of this, the alanine substitutions of Leu357 and Phe367 in mutants
PfAMA1/DIII-HA-HT2 and PfAMA1/DIII-HA-HT3 would be
expected to have a substantial destabilising effect on the interface
between domain I and the domain II loop. However, the ability of
PfAMA1/DIII-HA-HT3 to interact with both the AAP complex
(Figure 6C) and mAb 4G2 (Figure S1) suggests that the substituted
residues are not on their own critical for stabilisation of the domain II
loop. On the other hand, the clear absence of RON4 binding
displayed by mutants PfAMA1/DIII-HA-HTFY, PfAMA1/DIII-
HA-HTY and PfAMA1/DIII-HA-HT1 strongly implicate solvent-
exposed hydrophobic trough residues – and specifically the central,
completely conserved aromatic residue Tyr251 - as being key players
in AAP complex formation. The factthat this trough lies adjacent to a
cluster of residues we have previously shown to be required for 4G2
binding strongly suggests that it is the presence of bound AAPs that
selectively prevents interaction of mAb 4G2 with the PfAMA1-AAP
complex, presumably due to steric hindrance between these large
molecules or as a result of local conformational changes introduced
into PfAMA1 upon AAP binding. For the reasons laid out below, we
propose that the invasion-inhibitory activity of mAb 4G2 is a direct
result of this.
Several reports, including our own earlier studies [6,7], have
suggested that AMA1 translocates from micronemes to the
parasite surface well before interaction with the host cell surface.
For technical reasons (not least the difficulty of isolating invasive P.
falciparum merozoites) the precise timing of this relative to host cell
entry has not been demonstrated conclusively in P. falciparum.
However, in both P. knowlesi and Toxoplasma, AMA1 has been
clearly demonstrated on the surface of invasive and/or actively
invading merozoites and tachyzoites [7–10,12]. The fact that
monoclonal and polyclonal antibodies to AMA1 efficiently block
invasion in both genera, as well as in the related apicomplexan
Babesia [11], lends additional support to this, showing that surface-
resident parasite AMA1 is accessible to antibody prior to the point
of invasion. In contrast, current knowledge of RON4 trafficking
suggests that this protein does not relocalise to the parasite surface
with the same timing as AMA1. Detailed studies in Toxoplasma
[12,15,25] and our own analyses in P. falciparum (not shown, but
see e.g. Figure 3B) have shown that RON4 is not detectable in any
location other than the rhoptries prior to the point of initiation of
invasion, suggesting that its discharge to interact with AMA1 and
partake in moving junction formation occurs subsequent to
movement of AMA1 onto the parasite surface. Assuming that
trafficking of the other AAPs follows a similar pathway to that of
RON4 (RON2 is a rhoptry neck protein, and Ts4705/Mal8P1.73
is also likely rhoptry-derived; [30]) our data support the following
simple model. Discharge of AMA1 from micronemes onto the
parasite surface occurs at some point prior to interaction with the
host cell. Anti-AMA1 antibodies are able to immediately bind the
solvent-exposed protein. Upon host cell binding, and at or around
the point of junction formation, RON4 plus the other components
of the AAP complex are discharged from rhoptries, assembling
with the surface-resident AMA1 via the hydrophobic trough to
participate in formation of the moving junction. If – as in the case
of mAb 4G2 - the specificity of the bound antibody is such that it
blocks AMA1-AAP assembly, junction formation is impaired and
the entire invasion pathway is arrested at that point.
Clearly, one additional way to test the validity of the above
model would be to directly demonstrate that binding of mAb 4G2
to free PfAMA1 prevents assembly of the PfAMA1-AAP complex.
However, although the schizont extracts used in this study
contained free PfAMA1 and free AAP complex as well as pre-
formed complex, we were unable to detect any change in the
relative abundance of these forms over time. Also, depletion of the
free PfAMA1 with mAb 4G2 did not detectably destabilise existing
PfAMA1-AAP complex suggesting that, once the complex is
formed, the affinity between its constituents is high. On the other
hand, despite exhaustive efforts we have been unable to
reconstitute the complex in vitro using recombinant, correctly
folded PfAMA1 ectodomain and parasite-derived AAPs (C.
Collins and M. Blackman, unpublished), suggesting that assembly
of the complex may require specific conditions that cannot be
mimicked in crude detergent extracts. Other models are consistent
with our data – for example, it is possible that mAb 4G2 may
interfere with a distinct function for PfAMA1 in signal transduc-
tion – but we favour the above proposal because of the very clear
inability of mAb 4G2 to bind pre-formed PfAMA1-AAP complex.
It is worth noting that both the published x-ray crystal structures of
AMA1 reveal that segments of the domain II loop show signs of
extensive mobility. This is displayed either through weak or absent
electron density in the crystal structures, or high temperature
factors, whilst in the PvAMA1 structure the loop is very disordered
[17,18]. Thus, in addition to the possibility of simple steric
hindrance, one further possibility is that this mobility of the
domain II loop could be responsible for a cryptic AAP-binding site
that remains hidden until the ligand is present. Binding of mAb
4G2 to the domain II loop could block a conformational change in
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conformational change that is incompatible with AAP binding.
Determination of the three-dimensional structures of both the
AMA1-AAP complex and the PfAMA1-mAb 4G2 complex is now
required to reveal the complete details of how AAP binding
interferes with recognition of PfAMA1 by mAb 4G2, and vice versa.
Our findings add to a steadily accumulating dataset pinpointing
the importance of the hydrophobic trough in AMA1 function. As
pointed out by Bai and colleagues [18], the fact that the trough is
surrounded by polymorphic residues (including some of the most
polymorphic positions in the entire molecule), whilst residues
within the trough itself are highly conserved, suggests analogies
with receptor binding pockets in viral proteins such as influenza
haemagglutinin, where flanking polymorphisms enable antigenic
diversification to ‘escape’ neutralising antibody responses [31].
The 4G2 epitope is conserved across all known P. falciparum
isolates, but polymorphic residues critical for binding of the
invasion-inhibitory mAb 1F9 lie in close proximity to the
hydrophobic trough (Figure 5) [21,27]. The functional importance
of the trough and its flanking segments is further supported by the
recent demonstration that single chain antibodies targeting the
trough can prevent invasion [32], and the epitope recognised by a
protective P. yoelii AMA1-specific mAb localises to the domain II
loop [33]. Thus, there are substantial existing data highlighting the
hydrophobic trough as a functionally important region of AMA1.
By showing that residues within the trough are required for AAP
binding, and by demonstrating a link between epitope accessibility
and AMA1-AAP complex formation, our study provides the first
plausible mechanistic explanation for the invasion-inhibitory
activity of antibodies that recognise this region of AMA1
We found it surprising that the majority of the PfAMA1
mutations studied did not discernibly affect binding to PfRON4.
These include all the point mutations in residues implicated in
4G2 binding, in particular the Asp348Ala substitution in mutant
PfAMA1/DIII-HA-D348/A, which we have previously found to
affect the overall fold of PfAMA1 [24]. The fact that these mutants
retained their RON4 binding capacity suggests that the surface
involved in AAP formation is fairly localised – although it is very
likely larger than that encompassed by the single residue
substituted in the PfAMA1/DIII-HA-HTY mutant. Furthermore,
our observation that the anti-PfRON4 mAb 24C6 co-precipitated
both the mature 83 kDa and processed 66 kDa forms of PfAMA1
clearly demonstrates that prosequence removal is not a prerequi-
site for AAP binding. Our work also raises questions about the
topology of the complex. Our observation that the three AAPs can
be co-precipitated following depletion of PfAMA1 is consistent
with the findings of Lebrun et al. in Toxoplasma [15], showing that
the AAPs can interact independently of PfAMA1. It is conceivable
that the AAPs may traffic from the rhoptries as a pre-formed
complex. In the absence of antibody reagents to the other P.
falciparum AAPs identified here, PfRON2 and Mal8P1.73, we were
unable to ascertain whether these proteins can associate
individually with PfAMA1 in the absence of PfRON4 binding.
Further work is required to establish the association between the
various components, in particular the stoichiometry of the
interaction(s) and identification of the partner(s) that interacts
directly with PfAMA1. In this regard, it may be significant that in
their study showing an interaction between RON4 and PfAMA1,
Alexander et al. [13] did not observe any co-precipitation of any
other AAPs. The discrepancy between their results and our own
may be a result of the different conditions used for immunopre-
cipitation (e.g. their use of RIPA buffer, which contains
deoxycholate and SDS in addition to NP40), but whatever the
case their data suggest that at least RON4 can directly associate
with PfAMA1. Finally, whilst this manuscript was under peer
review, Cao and colleagues [34] published a study showing
formation of a complex between PfAMA1, PfRON4 and PfRON2
in mature schizonts, and confirming localisation of PfRON2 to the
rhoptry neck.
There is an increasingly urgent need for an effective
antimalarial vaccine, particularly against P. falciparum. It has long
been recognised that not all antibodies against AMA1 possess
invasion-inhibitory properties [19]. If interfering with assembly of
the PfAMA1-AAP complex is a common mechanism by which
invasion-inhibitory antibodies function, our observations may
inform the rational design of optimised sub-unit constructs that
specifically direct the humoral immune response towards the
production of antibodies targeting the PfAMA1-AAP interface.
Alternatively, it may be possible to identify small compounds that
bind the interface with high affinity and similarly block this critical
step in invasion.
Materials and Methods
Antibodies
Anti-PfAMA1 antisera were produced as described previously
by immunisation with recombinant PfAMA1 ectodomain (Ile97-
Lys546) expressed in Pichia pastoris using a synthetic codon-
optimised synthetic gene called ama-1syn [17,24,35]. Mouse serum
N5 and rabbit serum Rb1 were raised by immunisation with
native recombinant protein, whilst mouse serum R5 was raised by
immunisation with reduced and alkylated protein as previously
described [17,24]. The HA-specific mAb 3F10 (Roche) was used
for detection of HA-tagged proteins. Protein G Sepharose (GE
Healthcare) was used to purify rat mAb 4G2, a kind gift of Alan
Thomas (Biomedical Primate Research Centre, Rijswijk, The
Netherlands), from hybridoma culture supernatants. The
PfRON4-specific mouse mAb 24C6 [25] was a kind gift of Jean-
Franc ¸ois Dubremetz, University of Montpellier 2, France.
Construction of episomal expression plasmids
For episomal expression of PfAMA1 transgenes in P. falciparum,
a single HA epitope tag (YPYDVPDYA in single letter amino-acid
code; [36]) was introduced into a region of ama-1syn encoding a
loop in domain III. Structural analyses (not shown) making use of
the three-dimensional structure of PfAMA1 [17,18] indicated that
a tag at this location within the ectodomain would not affect
overall protein conformation. To introduce the tag, sequence
encoding 459KRIKLNDND467 in construct pST2A-sgPfa1 [24]
was modified to encode the HA tag by Quikchange site-directed
mutagenesis (Stratagene), resulting in construct pST2A-sgA1/
DIII-HA. To produce a construct for episomal expression of the
full-length HA-tagged protein (PfAMA1-DIII-HA) in P. falciparum
under control of the authentic ama1 promoter, sequence spanning
the HA tag was excised using StuI and AgeI (Roche) and cloned
into pHAM-sgPfa1/HA [24] restricted with the same enzymes,
giving rise to plasmid pHAM-sgA1/DIII-HA. For expression of
various mutants of PfAMA1-DIII-HA, appropriate mutations
were introduced into pST2A-sgPfa1 by Quikchange site-directed
mutagenesis, and sequence encompassing these mutations sub-
cloned by restriction with PstI and NcoI into pHAM-sgA1/DIII-
HA. Nucleotide sequences of all cloned products were confirmed
by sequencing on both strands.
Parasite culture and transfection
Blood stages of P. falciparum clone 3D7 were maintained and
synchronized in medium containing the serum substitute Albumax
using standard procedures [37]. Ring stage parasites at 5–10%
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of plasmid DNA as described previously [5]. Selection for lines
harboring the input plasmid was carried out using 10 nM
WR99210 (Jacobus Pharmaceuticals, New Jersey, USA). Synchro-
nous schizont preparations were frozen directly for IP analysis or
saponin-treated and analysed by Western blot. For analysis of
proteins released into culture supernatants, purified schizonts were
cultured for 8 h in medium without Albumax in the presence of
fresh human erythrocytes to allow reinvasion and shedding of
invasion proteins. Following clarification through a 0.2 mm filter
(Vivascience), culture supernatants were concentrated 50-fold
using a 10 kDa molecular mass cut-off Vivaspin 6 column
(Vivascience) before analysis by Western blot.
Immunoprecipitation, SDS-PAGE and Western blot
Cultures containing highly mature, synchronous schizonts were
metabolically labelled for 1 h in methionine-free medium
containing 100 mCi ml
21 L-[
35S]-methionine and L-[
35S]-cysteine
Promix
TM (GE Healthcare) as described previously [38]. Parasites
were washed and cultured for a further hour before being
harvested by centrifugation and storage at 280uC. Immunopre-
cipitation from Nonidet P40 extracts of the radiolabelled schizonts
was as described previously [38] using anti-PfAMA1 serum N5,
mAb 4G2, mAb 24C6 or normal mouse serum (NMS) as control.
Immunoprecipitated proteins were solubilised in SDS sample
buffer and subjected to SDS-PAGE under non-reducing or
reducing conditions followed by either fluorography or transfer
to Hybond-C extra nitrocellulose membrane (GE Healthcare).
Membranes were probed with mAbs or polyclonal antibodies as
described previously [38].
Proteolytic digestion and MALDI-TOF mass spectrometry
Immunoprecipitated samples were reduced and alkylated,
fractionated by SDS-PAGE, subjected to in-gel tryptic digestion
and digests analysed by MALDI-TOF mass spectrometry, all as
previously described [4].
Indirect immunofluorescence analysis (IFA)
Thin films of P. falciparum cultures containing mature schizonts
and naturally-released free merozoites were air-dried, fixed in 4%
(w/v) formaldehyde for 30 minutes (Agar Scientific Ltd.),
permeabilized for 10 minutes in 0.1% (w/v) Triton 6100 and
blocked overnight in 3% (w/v) bovine serum albumin in PBS.
Slides were probed with mAbs and polyclonal sera as described
previously [5], mounted in Citifluor (Citifluor Ltd., Canterbury,
U.K.), and images collected using AxioVision 3.1 software on an
Axioplan 2 Imaging system (Zeiss) using a Plan-APOCHROMAT
1006/1.4 oil immersion objective.
Molecular modelling of the PfAMA1 ectodomain
Coordinates for PfAMA1 domains I and II (PDB ID code 1Z40
and 2H86; [18]), and the complete PvAMA1 ectodomain (PDB ID
code 1W81 and 1W8K; [17]), which lacks electron density for
much of the domain II loop, were aligned and used to produce an
energy minimised model extending from residue 96 to 533, as
described previously [24]. Figures were created using PyMOL
(DeLano, W.L. The PyMOL Molecular Graphics System, 2002;
DeLano Scientific, San Carlos, CA, USA. http://www.pymol.org)
Supporting Information
Figure S1 Mutations within and flanking the hydrophobic
trough of PfAMA1 do not disrupt the overall conformation of
the molecule
Found at: doi:10.1371/journal.ppat.1000273.s001 (0.19 MB PDF)
Table S1 Peptides identified by MALDI-TOF analysis of RON4
tryptic digests
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Table S2 Peptides identified by MALDI-TOF analysis of
PfRON2 tryptic digests
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Table S3 Peptides identified by MALDI-TOF analysis of
Mal8P1.73 tryptic digests
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